Related references
Note: Only part of the references are listed.ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Alberto Puccini et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
Paolo Manca et al.
BRITISH JOURNAL OF CANCER (2022)
BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy
Koji Ueda et al.
EJSO (2022)
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
Christian Rolfo et al.
BRITISH JOURNAL OF CANCER (2022)
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Louise B. Callesen et al.
BRITISH JOURNAL OF CANCER (2022)
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer
M. Benavides et al.
ESMO OPEN (2022)
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2022)
Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
Antonio Avallone et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
Yoshinori Kagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi et al.
NATURE MEDICINE (2022)
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Jeanne Tie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Liquid biopsy: current technology and clinical applications
Mina Nikanjam et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
Jonathan D. Sorah et al.
ONCOLOGIST (2022)
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
Hiroki Osumi et al.
BMJ OPEN (2022)
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Gianluca Mauri et al.
CANCERS (2021)
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Paolo Manca et al.
CLINICAL CANCER RESEARCH (2021)
Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study
Yoshinori Kagawa et al.
CLINICAL CANCER RESEARCH (2021)
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Gongmin Zhu et al.
MOLECULAR CANCER (2021)
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Yoshiaki Nakamura et al.
NATURE MEDICINE (2021)
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
Hiroya Taniguchi et al.
CANCER SCIENCE (2021)
Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
Hiroki Osumi et al.
CANCER MEDICINE (2021)
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
Davide Ciardiello et al.
CANCERS (2021)
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
Pauline Gilson et al.
CANCERS (2021)
True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature
Chiara Nicolazzo et al.
CANCER LETTERS (2021)
NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature
Hiroki Osumi et al.
EUROPEAN JOURNAL OF CANCER (2021)
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
A. Rose Brannon et al.
NATURE COMMUNICATIONS (2021)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial
Erika Martinelli et al.
JAMA ONCOLOGY (2021)
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Emilie Moati et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Seyed Pairawan et al.
CLINICAL CANCER RESEARCH (2020)
NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type.
Jason Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer
Huiyan Luo et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing
D. C. L. Vessies et al.
SCIENTIFIC REPORTS (2020)
Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy
Hiu Ting Chan et al.
MOLECULAR ONCOLOGY (2020)
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
Susanne Klein-Scory et al.
FRONTIERS IN ONCOLOGY (2020)
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela et al.
CLINICAL CANCER RESEARCH (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
Ryan Woodhouse et al.
PLOS ONE (2020)
A mathematical model of ctDNA shedding predicts tumor detection size
Stefano Avanzini et al.
SCIENCE ADVANCES (2020)
Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
Chiara Nicolazzo et al.
CANCERS (2020)
Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
Mohamed Bouchahda et al.
JCO PRECISION ONCOLOGY (2020)
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer
Yu Sunakawa et al.
JCO PRECISION ONCOLOGY (2020)
Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis
Jicheng Wu et al.
THERANOSTICS (2020)
Clinical utility of circulating tumor DNA for colorectal cancer
Hiroki Osumi et al.
CANCER SCIENCE (2019)
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2019)
A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
Hideaki Bando et al.
BRITISH JOURNAL OF CANCER (2019)
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Natasha B. Leighl et al.
CLINICAL CANCER RESEARCH (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Emil Christensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G. Rothwell et al.
NATURE MEDICINE (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
FOLFIRI plus panitumumab as second -line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first -line FOLFOXICAPDX plus bevacizumab-based treatment: Phase II CONVERTIX trial
A. Fernandez Montes et al.
ANNALS OF ONCOLOGY (2019)
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Ana Vivancos et al.
SCIENTIFIC REPORTS (2019)
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Sergio Villatoro et al.
MOLECULAR ONCOLOGY (2019)
Targeting Oncogenic BRAF: Past, Present, and Future
Aubhishek Zaman et al.
CANCERS (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
N. Tarazona et al.
ANNALS OF ONCOLOGY (2019)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Pedram Razavi et al.
NATURE MEDICINE (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Jeanne Tie et al.
JAMA ONCOLOGY (2019)
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Marc Peeters et al.
CLINICAL CANCER RESEARCH (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
Cristina Raimondi et al.
CANCERS (2019)
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers
Tiziana Venesio et al.
PATHOBIOLOGY (2018)
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H. Strickler et al.
CANCER DISCOVERY (2018)
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Giulia Siravegna et al.
CANCER CELL (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
Jessica Garcia et al.
Oncotarget (2018)
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Ryan N. Ptashkin et al.
JAMA ONCOLOGY (2018)
Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy
Keishi Sugimachi et al.
BRITISH JOURNAL OF CANCER (2018)
481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
H Osawa et al.
ANNALS OF ONCOLOGY (2018)
543PGene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
Y Sunakawa et al.
ANNALS OF ONCOLOGY (2018)
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
Jesus Garcia-Foncillas et al.
BRITISH JOURNAL OF CANCER (2018)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Rick Kamps et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing
Wolff Schmiegel et al.
MOLECULAR ONCOLOGY (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
J. Garcia-Foncillas et al.
ANNALS OF ONCOLOGY (2017)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (vol 23, pg 2313, 2012)
D. Santini et al.
ANNALS OF ONCOLOGY (2017)
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Fanny Garlan et al.
CLINICAL CANCER RESEARCH (2017)
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Filip Janku et al.
CLINICAL CANCER RESEARCH (2017)
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs et al.
CELL STEM CELL (2017)
Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
J. Vidal et al.
ANNALS OF ONCOLOGY (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
Thomas Reinert et al.
GUT (2016)
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care
Safia El Messaoudi et al.
CLINICAL CANCER RESEARCH (2016)
Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer
Karin Birkenkamp-Demtroder et al.
EUROPEAN UROLOGY (2016)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Jeanne Tie et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
M. P. Morelli et al.
ANNALS OF ONCOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord
Yuxuan Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Ming-Tseh Lin et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
Karen-Lise G. Spindler et al.
ACTA ONCOLOGICA (2013)
Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas
Krishna B. Sriram et al.
BMC CANCER (2012)
Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
Karen-Lise Garm Spindler et al.
CLINICAL CANCER RESEARCH (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Analysis of the Size Distributions of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing
H. Christina Fan et al.
CLINICAL CHEMISTRY (2010)
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
Heidi Schwarzenbach et al.
BREAST CANCER RESEARCH (2009)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer
Suhail K. Mithani et al.
CLINICAL CANCER RESEARCH (2007)
Detection and quantification of mutations in the plasma of patients with colorectal tumors
F Diehl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma
K Ito et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
